Accelerating drug discovery through our single-cell technology
QuRIE-seq is our patented single-cell technology that enhances the drug discovery and development process.
It enables the decoding of cellular responses by simultaneously quantifying mRNA molecules, as well as hundreds of membrane proteins, intracellular proteins, and phosphoproteins.
The basis of QurieGen’s approach is our ability to “lock” biology to build timelapse maps of cellular responses.
Systems Biology
We believe that trained models outperform traditional trial-and-error testing and unravel novel biology. By utilizing a high-throughput proprietary approach for mapping cellular responses, combined with single-cell genomics and data science, we craft predictive models of disease biology and drug response. This innovative platform equips us to discover new drug targets, develop more efficient therapies, and streamline the time and costs involved in traditional drug discovery and development.
We add value at every stage of the drug discovery and development process
Discovery Phases
- Finding new drug targets and combinations.
- Selecting leads based on favourable cell response patterns.
Pre-Clinical Trials
- Providing a high-resolution, quantitative MoA plan.
- Early identification of unwanted toxicity and non-responsive cells.
Clinical
Trials
- View of the heterogeneity of cell response.
- Detection of resistant cells subsets and other reasons for failure.